Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

View Full Paper
Ask AI
Bookmark
Share

Authors

SYSung‐Soo YoonSeoul National UniversityGLGyeong‐Won LeeGyeongsang National UniversityHSHo‐Jin ShinEmory University

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows treatment strategies improve clinical significance of CHR and MR in polycythemia vera patients.

Key Points

  • To evaluate the durability of complete hematologic response (CHR) and molecular response (MR) in polycythemia vera patients receiving ropeginterferon alfa-2b.
  • Single-arm, open-label phase 2 study conducted in Korea at 16 institutions.
  • Polycythemia vera patients received rapid dose-escalation of ropeginterferon alfa-2b for 48 weeks.
  • CHR and MR assessed at regular 12-week intervals up to 108 weeks.
  • CHR rates increased from 26.6% at 12 weeks to 81.8% at 108 weeks.
  • Among patients achieving CHR, 68.4% maintained it long-term.
  • Higher baseline alkaline phosphatase levels were linked to sustained CHR.

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df77https://doi.org/10.1182/blood-2025-5598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera2025
  2. 2Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b2026
  3. 3Impact of early dose escalation and treatment duration on hematologic response in ropeginterferon alfa-2b treatment for polycythemia vera2025
  4. 4Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment2024 · 26 citations
  5. 5Long-term outcomes of ropeginterferon alfa-2b-njft in polycythemia vera: a review of safety, efficacy, and potential disease modification2026